In addition to the loss of the autoinhibitory region of BRAF, promoter regulatory elements from SLC45A3, which may be regulated by androgen (SLC45A3-BRAF) or promoter regulatory elements from ESRP1, lead to high expression of the chimeric transcript, which correlates with disease progression in prostate cancer metastases [53]. Here, ESRP1 is linked to prostate cancer.